Drugs / Ledipasvir/sofosbuvir
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02583685 Background | May 2015 → Oct 2024 | chronic hepatitis C virus infection | Humanity and Health Research Centre | Completed | No outcome recorded |
Press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ledipasvir/sofosbuvir | “Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily” NCT02583685 ↗ |
| Known as | LDV/SOF | “Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily” NCT02583685 ↗ |
| Route | Oral | “fixed dose combination (FDC) tablet administered orally once daily” NCT02583685 ↗ |